J&J’s Ortho Clinical Diagnostics Business Snapped up by Carlyle Group for $4.15 Billion in a Sale that Will Impact OCD’s Clinical Laboratory Customers

It’s finally official! Ortho Clinical Diagnostics  (OCD) will be sold to The Carlyle Group (CG: NASDAQ), an asset management firm and equity investor. The sales agreement was announced on Thursday. Carlyle will pay $4.15 billion, and the transaction is expected to close mid-year, pending regulatory approvals. OCD’s change of ownership will be closely watched by the thousands of medical laboratories in the United States and abroad that are customers of OCD. Typically, pathologists and clinical...

Australia’s Three Biggest Pathology Laboratories Face New Competitive Pressures

Less funding for clinical pathology laboratory testing is just one of several market developments Australia’s competitive market for clinical pathology laboratory testing seems poised for some major changes. Unfolding events are upsetting the pathology testing status quo in at least three ways. Caught in the middle of these disruptive forces are Australia’s big three of pathology testing: Healthscope Limited (ASX:HSP), Primary Health Care Limited (ASX:PRY), and Sonic Healthcare, Ltd. (ASX:SHL...
;